Open AccessPrediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia
Author(s) -
Olga Kalashnikova,
Ivan S. Moiseev,
Т. Л. Гиндина,
Е. А. Измайлова,
Maria Ivanova,
Elena Kondakova,
Н. Б. Михайлова,
Alexander Kulagin
Publication year - 2021
Publication title -
kliničeskaâ onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.116
H-Index - 2
eISSN - 2500-2139
pISSN - 1997-6933
DOI - 10.21320/2500-2139-2021-14-4-466-476
Subject(s) - hazard ratio , medicine , context (archaeology) , chronic lymphocytic leukemia , proportional hazards model , oncology , confidence interval , leukemia , biology , paleontology
Background. The emergence of signaling pathway inhibitors (SPI) considerably improved the prognosis in relapsed chronic lymphocytic leukemia (R-CLL). Nevertheless, some patients cannot achieve optimal and sustained response. TP53 gene defects determine the refractoriness to immunochemotherapy (ICT) and lower rates of progression-free survival on SPI therapy. However, the prognostic value of complex karyotype (CK) in CLL has long been disputed. In recent years, greater attention has been placed on the prognostic impact of CK in the context of SPI therapy. Materials & Methods. The study included 180 patients who received the drug treatment for R-CLL (113 of them with ICT, 67 of them with SPI). Their age at the onset of second-line therapy, the response to first-line therapy, early ( 65 years showed independent prognostic value. Conclusion. Standard karyotyping of peripheral lymphocytes with specific stimulation establishes a clearer disease prognosis and suggests the optimal choice of R-CLL treatment strategy.